Egetis receives US notice of allowance for MCT8 deficiency composition patent

Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial

Halozyme reports US FDA approval of TECVAYLI in combination with DARZALEX FASPRO for relapsed/refractory multiple myeloma

Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg

Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial

Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM

Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation

Sanaregen receives FDA clearance for retinal degeneration clinical trial

Esperion to acquire Corstasis, expanding cardiovascular portfolio

ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117

BD receives FDA clearance for Surgiphor 1000mL irrigation system

United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study

FDA accepts rusfertide NDA and grants priority review for polycythemia vera

UAE approves PYRUKYND for treatment of thalassaemia

Eli Lilly's Olumiant (baricitinib) receives positive European regulatory opinion for approval to treat adolescents with severe alopecia areata